|
業務類別
|
Biotechnology |
|
業務概覽
|
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology. |
| 公司地址
| One Main Street, Suite 1350, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 617 410-4650 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cullinantherapeutics.com |
| 員工數量
| 109 |
| Dr. Jeffrey Alan Jones, M.D. |
Chief Medical Officer |
美元 529.80K |
28/04/2026 |
| Dr. Corinne Savill, PhD |
Chief Business Officer |
-- |
28/04/2026 |
| Dr. Jennifer Michaelson, PhD |
Chief Scientific Officer |
-- |
28/04/2026 |
| Mr. Nadim Ahmed |
Director, President and Chief Executive Officer |
美元 698.48K |
28/04/2026 |
| Ms. Mary Kay Fenton |
Chief Financial Officer and Principal Accounting Officer |
美元 512.33K |
28/04/2026 |
| Ms. Jacquelyn L. Sumer |
Chief Legal Officer, Chief Compliance Officer and Secretary |
-- |
28/04/2026 |
|
|
| Mr. Nadim Ahmed |
Director, President and Chief Executive Officer |
28/04/2026 |
| Mr. Stephen W. Webster |
Independent Director |
28/04/2026 |
| Mr. Anthony Rosenberg |
Chairman of the Board |
28/04/2026 |
| Dr. Andrew R. Allen, M.D.,PhD |
Independent Director |
28/04/2026 |
| Ms. Mary T. Thistle |
Independent Director |
28/04/2026 |
| Mr. David D. Meek |
Independent Director |
28/04/2026 |
| Dr. Mittie Doyle, F.A.C.R.,M.D. |
Independent Director |
28/04/2026 |
|
|
|
|
